Dual Approach to Disease: Eli Lilly’s Zepbound-Taltz Combination Demonstrates Breakthrough Results in Psoriasis Treatment

Eli Lilly is making strategic moves to expand its obesity medication Zepbound beyond weight management, demonstrating promising results when combined with its autoimmune therapeutic Taltz for treating patients with both…

Continue Reading Dual Approach to Disease: Eli Lilly’s Zepbound-Taltz Combination Demonstrates Breakthrough Results in Psoriasis Treatment

Once-Daily Zasocitinib Delivers Clear Skin for Psoriasis Patients: Takeda’s Landmark Phase 3 Victory

Takeda Pharmaceutical Company has announced breakthrough results from Phase 3 trials of zasocitinib (TAK-279), an innovative oral treatment for moderate-to-severe plaque psoriasis that offers patients a promising new option for…

Continue Reading Once-Daily Zasocitinib Delivers Clear Skin for Psoriasis Patients: Takeda’s Landmark Phase 3 Victory

FibroBiologics Advances Innovative Cell Therapy: FDA Review of CYPS317 for Psoriasis Treatment Marks Major Clinical Milestone

FibroBiologics Inc, a clinical-stage biotechnology company, has announced a significant breakthrough in regenerative medicine by submitting a Phase 1/2 Investigational New Drug (IND) application to the US Food and Drug…

Continue Reading FibroBiologics Advances Innovative Cell Therapy: FDA Review of CYPS317 for Psoriasis Treatment Marks Major Clinical Milestone
Phase 3 Results: Imsidolimab Provides Positive Outlook in Generalized Pustular Psoriasis (GPP)
source: shutterstock.com

Phase 3 Results: Imsidolimab Provides Positive Outlook in Generalized Pustular Psoriasis (GPP)

Just about one month ago, clinical-stage biotechnology company AnaptysBio announced the availability of positive top-line results from two Phase 3 clinical studies: GEMINI-1 and GEMINI-2. Both studies sought to assess…

Continue Reading Phase 3 Results: Imsidolimab Provides Positive Outlook in Generalized Pustular Psoriasis (GPP)